-
2023-503793-20-00
5
2023-01-18
Prevention of ischemic stroke in patients post acute non-cardioembolic
-
2024-511621-64-00
4
2023-01-18
Acute kidney injury
-
2022-500186-27-00
5
2023-01-11
ATTR Amyloidosis
-
2022-500424-30-00
4
2022-12-28
Parkinson’s disease
-
2024-517377-24-00
3
2022-12-20
Subjects with AML ( Acute myeloid leukaemia) or MDS (Myelodysplastic s
-
2024-513230-38-00
5
2022-12-15
Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peri
-
2024-512621-88-00
4
2022-12-06
Acute Respiratory Distress Syndrome
-
2022-500652-37-00
4
2022-12-01
Advanced melanoma refractory to prior checkpoint inhibitor therapy
-
2023-504350-36-00
1
2022-11-25
Advanced non-small cell lung cancer with or without NFE2L2/KEAP1/CUL3
-
2024-513262-19-00
5
2022-11-21
Thrombotic Thrombocytopenic Purpura
-
2022-503144-40-00
5
2022-11-17
Pneumococcal disease
-
2023-506193-12-00
4
2022-11-10
Newly Diagnosed Medulloblastoma
-
2023-503529-20-00
4
2022-10-17
BRCA Mutations and Early Stage HER2-Negative Breast Cancer
-
2023-506772-28-00
4
2022-10-07
Ewings Sarcoma
-
2024-512803-37-00
5
2022-10-05
Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)
-
2024-510729-24-00
6
2022-09-01
Chronic Migrane, Migrane, Medication Overuse Headache
-
2023-503797-21-00
5
2022-08-10
Metastatic Colorectal Cancer
-
2024-513658-31-00
4
2022-08-08
Idiopathic Sudden Sensorineural Hearing Loss
-
2024-513614-36-00
9
2022-07-27
Immune related adverse events induced by treatment with
immunotherapy
-
2024-515485-14-00
5
2022-07-07
Acute major bleeding in patients receiving DOAC therapy with factor Xa
-
2023-509998-23-00
7
2022-06-21
Wilson's Disease
-
2024-511706-23-00
4
2022-05-31
Focal segmental glomerulosclerosis
-
2024-511975-14-00
9
2022-05-26
recurrent/refractory Ewing sarcoma
-
2023-505441-69-00
5
2022-05-17
refractory, advanced gastro-oesophageal cancer